Education and Training
- Fellow, Infectious Diseases, Duke University School of Medicine, 2008 - 2010
- Resident, Internal Medicine, Duke University School of Medicine, 2005 - 2008
- M.D., Wake Forest University, 2005
Huang, DB, Corey, GR, Holland, TL, Lodise, T, O'Riordan, W, Wilcox, MH, File, TM, Dryden, M, Balser, B, Desplats, E, and Torres, A. "Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections." International Journal of Antimicrobial Agents 52, no. 2 (August 2018): 233-240.
Holland, TL, O'Riordan, W, McManus, A, Shin, E, Borghei, A, File, TM, Wilcox, MH, Torres, A, Dryden, M, Lodise, T, Oguri, T, Corey, GR, McLeroth, P, Shukla, R, and Huang, DB. "A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)." Antimicrobial agents and chemotherapy 62, no. 5 (May 2018).
Huang, DB, O'Riordan, W, Overcash, JS, Heller, B, Amin, F, File, TM, Wilcox, MH, Torres, A, Dryden, M, Holland, TL, McLeroth, P, Shukla, R, and Corey, GR. "A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 66, no. 8 (April 2018): 1222-1229.
Huang, DB, Strader, CD, MacDonald, JS, VanArendonk, M, Peck, R, and Holland, T. "An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria." Open Forum Infectious Diseases 5, no. 2 (February 1, 2018).
Holland, TL, and Fowler, VG. "Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST." Lancet (London, England) 391, no. 10121 (February 2018): 634-636.
Stergiopoulos, S, Calvert, SB, Brown, CA, Awatin, J, Tenaerts, P, Holland, TL, DiMasi, JA, and Getz, KA. "Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 66, no. 1 (January 2018): 72-80.
Ruopp, MD, Boggan, JC, Holland, TL, Stillwagon, MJ, Govert, JA, and Bae, JG. "Missing the Mark: Inaccuracy of administrative data in identification of hospitalized patients with pneumonia and results of a systematic clinical reclassification process on readmission rates." Journal of Hospital Administration 6, no. 6 (October 16, 2017): 35-35.
Neuss, MJ, and Holland, TL. "Digital ischaemia after intra-arterial drug injection." BMJ case reports 2017 (September 25, 2017).
Clifton, DC, Clement, ME, Holland, TL, Cox, GM, Dicks, KV, and Stout, JE. "Suboptimal HIV Testing Among Patients Admitted With Pneumonia: A Missed Opportunity." AIDS education and prevention : official publication of the International Society for AIDS Education 29, no. 4 (August 2017): 377-388.
Doernberg, SB, Lodise, TP, Thaden, JT, Munita, JM, Cosgrove, SE, Arias, CA, Boucher, HW, Corey, GR, Lowy, FD, Murray, B, Miller, LG, Holland, TL, and Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG), . "Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 64, no. suppl_1 (March 2017): S24-S29. (Review)